Meet some of our RPS Fellows

Meet some of our recently-appointed Fellows

Susan Mann

I have always considered myself very fortunate, in that once I had decided to study Pharmacy, I knew I wanted to work in the industrial sector. I wanted to be involved in the development and manufacture of medicinal products that make a difference and help improve the quality of life for patients.

I joined the industry initially in a technical support role for production, then moved into quality assurance as an operational quality representative, giving me the opportunity to see all aspects of manufacture and control of a wide range of medicinal products. Many active substances and packaging components were also made on site, so this provided even broader experience. It also, of course, gave me hands on experience of what can and occasionally does go wrong! In these roles, I became very familiar with the requirements for Good Manufacturing Practice (GMP). The pharmaceutical industry must adopt these as it is very highly regulated.

My boss encouraged me to consider becoming a “Qualified Person” (QP) I sat my oral viva at the old RPS building near Lambeth Palace, passed, and became a QP in the mid 1980’s. Since then, I have spent much of my career in various quality assurance roles, from operational through to senior management, culminating with the role of VP International QA responsible for GMP compliance for both development and commercial medicinal products. 

Over 20 years ago I was invited by the Chair of the RPS QP Assessors group to become a QP Assessor. In this voluntary role, I review application forms and conduct Vivas for prospective QPs as part of a panel.

I started my own consultancy in 2009, wanting to share the knowledge and experience I had gained in the industry and as a QP. In this capacity, I have assisted start-up companies to develop and implement appropriate quality systems to support the work they perform. I have also assisted larger companies to streamline their quality systems to improve both efficiency and effectiveness. I have helped many companies prepare for successful regulatory inspections and helped others to deal with the outcomes of a poor GMP inspection.

A few years ago, I was invited by UNIDO (United Nations International Development Organisation) to join a small team of Good Manufacturing Practice (GMP) experts involved in a project to strengthen local manufacture of medicinal products in East Africa. After initial training in Vienna, I joined a team of 3; each assessing manufacturing sites on our own, according to agreed guidelines and WHO standards.
UNIDO had already spent time in each country completing the groundwork by liaising with the industry, regulators, and government officials to ensure each project had the maximum chance of success. The project that initially began in East Africa, was later rolled out in some West African countries. Each GMP expert assessed individual companies who had signed up to the initiative and were interested in achieving the standards required to gain valuable site accreditation to WHO GMP standards. I conducted GMP assessments of their premises, equipment/utilities and the quality system which should describe and support all activities being performed. At each assessment, I was accompanied by a local regulatory authority inspector to demonstrate transparency and consistency. 

In several countries, I also had the opportunity to attend meetings with various Ministers of Health and Trade Organisations. These initiatives are critically important in helping countries become more reliant on the domestic manufacture of cost effective, quality medicines for the local market and this in turn can often also open additional export markets to them. Each visit, I would typically spend 2 weeks in country and complete 5 company/site assessments each of 2 days. Hard work and long reports to complete, but definitely worth it. I enjoyed the challenge of considering cost effective solutions and improvements that companies typically with quite limited resources would be able to complete in pursuit of accreditation to WHO GMP standards. In all countries, I was respected as a Pharmacist, with many of experience of EU and WHO GMP requirements.

I was also able to make several return visits to review action plans for improvement at various sites and perform some re-assessments of both sites and systems. This gave me the opportunity to provide support and encouragement to these companies and to actually see the improvements that had been made.  

More recently, in addition to my consultancy, auditing and training work, I have been involved in another project for UNIDO, supporting a country in a different area of the world wanting to implement EU GMP standards to ensure appropriate quality and consistency of all medicinal products manufactured and supplied. For this project, I have been involved in numerous training courses on a range of topics associated with GMP. This in turn has led to some 1:1 coaching sessions with individual companies. It is very satisfying to see how in all cases, the companies develop a greater understanding of the regulations and guidelines (whether WHO or EU) associated with their operations and are empowered to implement changes that will assist them comply with the requirements.

I have been a Pharmacist and worked in the industry for over 40 years. I continue to have a varied and fulfilling career and am delighted to see more opportunities for those wanting to enter the industry. 

What does being a Fellow mean to me?

I am both delighted and humbled to have been nominated as a Fellow of the RPS. It will motivate me further to helping others during their various career journeys. It is an honour to realise that my contributions have been recognised.

Peter Morgan

Peter is currently the Medicines Net Zero Assistant Director for NHS England, leading the national strategy and policy work to reduce the medicines carbon footprint of the NHS in England. This work comes from the demand side, including levers such as high quality, low carbon inhaler care and the reduction in waste anaesthetic agents, to the supply side, working with medicines manufacturers and supply colleagues across the pharmaceutical industry.

After graduating from the University of Bath in 2013, Peter completed his pre-registration year in Nevil Hall Hospital in Abergavenny, Wales before moving to London where he started at King's College Hospital as an aseptic pharmacist. After realising his passion for this critical high impact area of pharmacy he quickly progressed into leadership roles. Peter chaired the London and South East Aseptic Services Managers group where he set up a workforce and research workstream; as well as sat on the Pharmaceutical Aseptic Services Group. In 2018, Peter undertook the Chief Pharmaceutical Officer's Clinical Fellowship Scheme giving him unparalleled exposure to pharmacy and healthcare leadership where he started to realise the importance of pharmacy/medicines leadership in tacking the climate crisis. After the fellowship, Peter returned to King's as Associate Chief Pharmacist - Aseptic Services where he oversaw two large capital projects and managed a critical cross-site CIVAS service during COVID all whilst developing and growing the Aseptic service, ensuring it continues to maintain the best patient care into the future.

Knowing the climate emergency is a health emergency and the vital role that pharmacy staff have in tackling it, Peter joined forces with other pharmacists to cofound Pharmacy Declares; climate conscious pharmacy professionals based in the United Kingdom calling for divestment, declaration, climate-health leadership & education. Pharmacy Declares went on to support numerous pharmacy organisations, including the RPS, to meet these objectives. Peter’s passion for sustainability, EDI and health inequalities continued to grow as he championed for these to be a part of pharmacy practice and calling for leadership in these areas from pharmacy organisations.

Peter then moved into his current role in NHS England working within the medicines policy and analysis unit leading the Medicines Net Zero Team, a Greener NHS workstream. The NHS was the first healthcare system in the world to commit to Carbon Net Zero and medicines currently make up 25% of the carbon footprint of the NHS in England, a key priority area for Net Zero. The team supports identification, empowerment and leadership working towards decarbonisation across both supply and usage of medicines. 

What does being a Fellow mean to me?

I was thrilled upon finding out that I was not only nominated but awarded an RPS Fellowship. This Fellowship is recognition that pharmacy professionals have a role in tackling the climate crisis and that doing so is recognised by our professional body. I am excited to represent the RPS as a Fellow, using my platform to bring more awareness to the climate crisis and show what we, as pharmacy professionals, can do to ensure a healthy future for our patients and planet.

Peter Mulholland

Peter Mulholland is currently a neonatal pharmacist at the Royal Hospital for Children in Glasgow. In addition he is the lead pharmacist for immunoglobulins for NHS Greater Glasgow and Clyde Health Board, and the lead pharmacist for Procurement Strategy for the board.

Peter qualified from the University of Strathclyde in 1981. His first senior role was as the Quality Control pharmacist at the Southern General Hospital in Glasgow, from here he took on the lead for pharmacy computer services. Peter attained membership of the College of Pharmacy Practice by examination in 1993. This was converted to a MSc in Clinical Pharmacy in 1997 at Liverpool John Moore’s University, and Fellowship of the College was awarded in 2007, following assessment against the Competency Development and Evaluation Group (CoDEG) standards. He was the second recipient of the College’s Bamford Silver Jubilee cup, in 2008. He acted as a tutor, and assessor, for the Scottish Hospital Pharmacy Vocational Training Scheme, which provides a clinical development programme for junior pharmacists.

Peter's main clinical role and research role has always been the care of neonates. He joined the Neonatal and Paediatric Pharmacists Group (NPPG) on its foundation in 1994 and has been involved with the group ever since, joining the committee in 1997. This resulted in taking on roles that would not necessarily be associated with a pharmacist working in Scotland, such as membership of the NPSA group, looking at care bundles for gentamicin use in neonates and, more recently, one of two pharmacists on the NICE Guideline development group for neonatal parenteral nutrition and the subsequent development of Quality Standards for the group.

What does being a Fellow mean to me? 

Throughout my career I have been fortunate to have bosses who have allowed and supported me to develop my varied roles. I am also passionate about developing junior pharmacists to reach their full potential. None of this is possible without the additional support of professional development organisations either at a specialist level such as NPPG, or at a national level like the RPS. I am honoured to have had my work recognised with Fellowship of the Royal Pharmaceutical Society.


Dr Amira Guirguis

Dr Amira Guirguis

Amira originally trained as an accountant, has pursued a career as a pharmacist and gained her PhD in the in-field detection of New Psychoactive Substance (NPS). She has worked in community and hospital pharmacy, and as an academic and researcher. 

After completing a BSc in Accountancy, Amira pursued her Pharmacy degree at the University of Hertfordshire. Amira worked in community and hospital pharmacy before pursuing her interests in academia and research. Amira had a passion for combining science and practice, so as she was completing her PhD on novel psychoactive substances and their detection, she was leading on national borough-level talks with service providers to raise awareness about these novel drugs, highlighting the role of the pharmacist in reducing harms from these drugs. Amira was very passionate about Foundation pharmacists (previously known as pre-registration pharmacists) and was engaged in their education and training with providers such as ProPharmace. She’s been also involved in the training of designated supervisor (previously known as tutors) training, and the ProPharmace/HEE Educational and Practice Supervisors training of pharmacy team members across sectors.

Amira is particularly known for the breadth of her knowledge and experience in drug detection particularly the novel psychoactive substances, where she has made major contributions through her PhD and to the trial of drug checking in community substance misuse services in collaboration with (Addaction). The project piloted the first home licensed service and had a great impact on drug policy in the UK.

Amira sits on CD national Boards to advise and share information on matters related to controlled drugs and substances with a potential for misuse and/ or diversion. This is owing to Amira’s expertise in current projects that she co-supervises with colleagues from Swansea University, the University of Hertfordshire and the University of Anglia Ruskin on pharmacovigilance and medicines diversion, drug abuse and mental health, opioid use disorders, smuggled drug detection in prisons, evaluation of healthcare professionals’ knowledge and response to people who use novel psychoactives, and analysis of drugs on the web to improve preparedness to future threats. 

Amira is known for promoting the role of the pharmacist in reducing drug related harm through national and international forums. Amira is committee member of the Joint Pharmaceutical Analysis Group (JPAG) and the Geoffrey Philips Award Chair, she is a member of the RPS Science and research Committee and a Board member of the RPS Medicines, Ethics and Practice. Amira was also on the Women to Watch List 2020.

Amira is now the Programme Director of the 4-Year MPharm and the 5-Year MPharm with a Foundation (Preparatory) Year at Swansea University. Amira contributed to the early development and establishing of these programmes, which welcomed their first cohorts in September 2021. 

What does being a Fellow mean to me?

It is an honour to have been designated a Fellow of the Royal Pharmaceutical Society. It is humbling to be recognised by my peers. I was incredibly fortunate to have worked with inspiring pharmacists and colleagues within the profession and from the wider healthcare team.

Dr Paul Goggin


Paul has been a practising pharmacist for nearly 30 years and is currently the Global Head of Switch (Science) at Sanofi.  Paul is known for pursuing his interest in the pharmacy profession initially “the hard way”. Paul started his career as an NHS ancillary worker in the Sterile Products Unit at Kent and Canterbury Hospital, went on to train as a pharmacy technician and combined a full-time job, with day release to study Pharmaceutical Sciences BTEC as well as ‘A’ level chemistry at night school to pave his way to studying for a Pharmacy degree. 

After completing his Pharmacy degree at Brighton, Paul pursued his interest in clinical pharmacy and passion for science with pre-registration training at Guys Hospital, and post-graduate research at University College London, leading to his Doctorate in 1996. Paul is particularly known for the breadth of his knowledge and experience in pharmaceutical formulation science, where he has made a major contribution to the development of many medicines by virtue of his strong formulation design knowledge and expertise, focusing around patient needs. These include - transdermal products (Elan) - soft gel and fast melts (R P Scherer and Pfizer) -  a novel, patented oropharyngeal delivery system (Pfizer) - Oral, dermal, and inhaled products (Vectura). Paul’s CV lists a significant number of patents which he had filed and/or held, which is a great recognition of the innovation employed in these varied formulation design projects.

In 2007, Paul re-joined Pfizer to lead a research group focused on product enhancement. Paul is known for combining a deep knowledge of drug formulation and delivery with focus on clinical outcomes. A key achievement during this phase of his career was the design and development of a novel “in house” orally disintegrating tablet platform for both Viagra® and Norvasc®.

Paul’s interest in the relationship between drug delivery and clinical outcomes is clearly shown through his numerous publications. These include peer-reviewed pharmaceutical science papers and presentations, in addition to many publications related to patient prescribing across a broad range of therapeutic areas. Paul is also known for his enthusiasm and commitment in developing others and specifically, supporting the training of pharmacists. Paul has held long-term teaching commitments to two of the London Pharmacy Schools at UCL and KCL. Paul has been a visiting lecturer at these two schools of pharmacy for more than 20 years, and he has provided this support while doing a full-time, demanding role in industry. 

It is testament to his enthusiasm and passion for education of pharmacists, that Paul has dedicated his personal time to support these establishments. He was also a key member of the Pfizer pre-registration team from 2007 – 2011. During this time, Paul helped build a successful partnership with several hospital and community pharmacies in order to offer industrial pre-registration placements. Paul was an inspiring tutor, promoting the role of the industrial pharmacist, always ensuring a close focus on patient needs. 

In 2011 Paul switched from product development to medical affairs and took a position as Senior Director with the newly created Pfizer Consumer Healthcare. Thanks to his knowledge of the science behind Viagra® and his familiarity with international pharmacy, he was asked to head up the medical team that would go on to switch Viagra® from Rx to OTC in several markets. This work involved Paul talking to over 1000 pharmacists around the world to understand what pharmacists needed in order to ensure that men got the right advice as to whether they should use the product. This 8-year programme involved consultation with many regulatory agencies (FDA, TGA, EMA, MHRA etc), medical organisations and pharmacy associations including the Royal Pharmaceutical Society. The latter were invaluable in the development of pharmacy facing education and training and the results of this work can be found at

During this time Paul also worked on various other innovative switch programmes in pain management, women’s health, sleep disorders and in GI health, where again he demonstrated his commitment to pharmacy by working with pharmacists all over the world on the successful Nexium® reclassification. He now heads the switch group at Sanofi. In summary, Paul is known for promoting the role of the pharmacist, for innovative product development, for supporting Rx to OTC switches, and for considering the patient perspective as a guiding principle of his work.

What does being a Fellow mean to me?

I have been lucky to work with many inspiring pharmacists and other scientific experts during my career and it is testament to these individuals. 

At Brighton this included the excellent teaching staff at the time, including Professors Marriott, Martin, Gard, Horne, Davies and the legendary Pam Graham. At Guys, I worked with the Andy Kostrzewski, Douglas Maclean and later with Aamer Safdar. At UCL School of Pharmacy, Professors Craig, Taylor, Bates and Gaisford and Drs Lloyd and Williams and of course Dave McCarthy. Thanks to all the “SOPSAP” cricketers making it a very enjoyable time. 

At KCL Professors Martini, Martin, Marriott Hylands and Brown. Special mention to Dr Graham, Jackson, Dr David Edwards, Professors Hackett Giuliano, and Kirby, to Dr Irwin Goldstein and Dr Terry Maguire. 

Thanks to all of those in our industry colleagues past and present, you know who you are!! Huge thanks to Professor John Staniforth, Drs Williams, Clarke, Bajwa and McGovern for their support and guidance.

Finally, to Paul Knowles who walked with me on the early journey, to my family, my children and above all Nicola, who made this all possible, I share this honour with you.

Babir Malik

Babir Malik

Babir Malik is currently the Weldricks Pre-reg Lead and Teacher Practitioner at the University of Bradford. He also practices as a relief pharmacist for Weldricks Pharmacy in Scunthorpe.

Babir began his pharmacy journey in 2003, at the University of Bradford, after completing a Biomedical Sciences degree previously at the same university. In 2007, upon graduating, he undertook his pre-registration training with Weldricks Pharmacy, whereby he then embarked on a Postgraduate Diploma in Community Pharmacy at Keele University in 2009. Babir has also completed his RPS Faculty journey and is at Stage 1.

One of his most enjoyable roles is being a Charity Ambassador for the Pharmacist Support. As part of this he jumped out of a plane in 2018 and helped raise over £1500. He is an RPS Mentor, Conference Panel member for the RPS Pre-registration conferences and on the MEP Advisory Board.

After many attempts for a role in academia, he successfully became Weldricks Teacher Practitioner, at the University of Bradford. As a Teacher Practitioner, his role includes being the Calculations Lead for the School of Pharmacy and Medical Sciences. Furthermore, Babir undertook a 10 week secondment as a Clinical Commissioning Group Pharmacist early in 2016. Babir also sits on the Chemist and Druggist Clinical Advisory Board.

Babir actively supports pre-registration pharmacists via his many social media groups and he works with a variety of organisations including the  RPS, Green Light Campus, PCPA and the British Islamic Medical Association to run sessions for pre-registration pharmacists. He is also the PCPA National Early Careers Lead and Ontrack Question Writer and Reviewer.

He has been a Pre-registration Tutor as well as sitting on the Rotherham Local Pharmaceutical Committee alongside being a Dementia Friend Champion, whereby he has generated over 300 dementia friends. He is also a UKCPA Community Pharmacy Group Committee Member.

In June 2016, his pharmacy in Scunthorpe was awarded the Chemist and Druggist Medicines Optimisation Award for their innovative LPS Intervention Service.

He is quite active on social media and enjoys interacting with the whole pharmacy community and has also written two popular light-hearted books about pharmacy in 2013 under the pseudonym “Mr Dispenser”. He wrote 100 questions for the ‘Pharmacy Registration Assessment Questions’ book which was released in April 2016 and recently released a ‘Pharmacy Law Quizzes’ short book. He has spoken at many conferences across the UK and has been invited to speak at overseas events in Ireland, France, Holland and Jersey.

What does being a Fellow mean to me?

I am honoured to be a Fellow after 12 years of practice. For me, being a pharmacist means helping others even after I finish work in the pharmacy or leave the lecture room. I have been incredibly fortunate to meet some amazing individuals who have inspired me and constantly push me to do more. They all have one thing in common: they are members of the RPS.

Jatinder Harchowal

Jatinder Harchowal

Jatinder Harchowal is currently Chief Pharmacist in the Royal Marsden Hospital (RMH) and is currently the Chair of the Royal Pharmaceutical Society’s Hospital Expert Advisory Group. Jatinder was previously Chief Pharmacist in Brighton & Sussex University Hospitals NHS Trust and Ealing Hospital.

I qualified in 1991 after completing the four-year integrated degree at the University of Bradford. My first job as a pharmacist was as a basic grade in the Queen Elizabeth Hospital, Birmingham, where I completed my postgraduate diploma in clinical pharmacy in 1993. I then moved to London as resident pharmacist in Lewisham Hospital before moving to Charing Cross Hospital to work in clinical services and clinical trials. In 1995, I moved to King’s College Hospital as their renal specialist pharmacist which was an area of huge interest to me and I was fortunate to be part of the UK Renal Pharmacy Group committee and helped edit the first edition of the Renal Drug Handbook.

I spent six years in King’s and eventually became the Associate Director of Pharmacy there before leaving in 2001 having obtained an MSc in Clinical Pharmacy Practice from London School of Pharmacy and a Diploma in Management Studies from Kingston University. After a year of travelling, I came back to the UK and worked as Clinical Services lead in Barts and the London before becoming Chief Pharmacist and Assistant Director of Operations in Ealing Hospital in 2004. After 5 years at Ealing, I was appointed as Chief of Pharmacy in Brighton & Sussex University Hospitals (BSUH) where I stayed from 2009-2014. Whilst at BSUH, I completed a Masters in Leadership and Quality Improvement (Generation Q). In 2014, I was appointed as Chief Pharmacist / Clinical Director for Clinical Support Services in the Royal Marsden NHS Foundation Trust. My interest in continuous improvement has allowed me to recently be seconded as Head of Quality Improvement in the Marsden and in 2020, I was privileged to be seconded as Director of Pharmacy for the Nightingale Hospital, London, helping set the hospital up and run the pharmacy service.

What does being a Fellow mean to me?

I have always tried to promote the profession in every job I have undertaken and believe in giving my teams the opportunity to showcase their skills as I feel proud in what we can achieve together. To have been made a Fellow of the RPS and have received this recognition by my peers is both humbling and a privilege. Thank you.

Dr Victoria Silkstone

Dr Victoria Silkstone qualified as a pharmacist from the University of Bradford in 1995 having undertaken pre-registration training at the Norfolk and Norwich Hospital and an independent community pharmacy in Bradford. She completed a PhD in inhalation drug delivery and has spent the next 20 years in pharmacy education inspiring and developing the next generation of pharmacists.

Victoria commenced a PhD immediately after qualification focused around inhalation drug delivery, alongside working as a community pharmacist. She has maintained an interest in in drug delivery and this has formed the basis of her collaborations with the pharmaceutical industry as part of her current role at the University of Manchester. 

Following completion of her PhD Victoria joined Bradford School of Pharmacy firstly as Boots Teacher Practitioner and then as Placements Tutor for the 5-year MPharm and was later promoted to Programme Leader for the 5-year intercalated MPharm.

In 2013, she joined the University of Manchester, where she introduced an innovative programme of community pharmacy, general practice and industrial placements within the MPharm programme. Victoria was also pivotal to the development of North West Centre for Advanced Drug Delivery (NoWCADD), a partnership between The University of Manchester and AstraZeneca. As part of this, she designed an innovative educational strategy which aims to equip and inspire undergraduate students to become pharmaceutical scientists of the future. This is achieved through collaborating closely with AZ staff on input into the curriculum, unique placements as well as joint undergraduate research projects. This unique industrial partnership within the Manchester curriculum is becoming one of the most attractive aspects for MPharm applicants, particularly for those with a longer term interest in industry careers. 

What does being a Fellow mean to me? 

I am passionate about being both a pharmacist but also inspiring the next generation of pharmacists that will work across sectors with the overall aim of improving patient care. I am delighted to be recognised as a fellow and truly believe that as a profession we need the Royal Pharmaceutical Society to provide leadership for the wider profession.